Physiotherapy and occupational therapy and mild to moderate parkinson disease-reply by Clarke, Carl E et al.
 
 
Physiotherapy and occupational therapy and mild to
moderate parkinson disease-reply
Clarke, Carl E; Walker, Marion F; Sackley, Catherine
DOI:
10.1001/jamaneurol.2016.1283
License:
None: All rights reserved
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Clarke, CE, Walker, MF & Sackley, CM 2016, 'Physiotherapy and occupational therapy and mild to moderate
parkinson disease-reply', JAMA Neurology. https://doi.org/10.1001/jamaneurol.2016.1283
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked 14/06/2016
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Copyright 2016 American Medical Association. All rights reserved.
Letters
COMMENT&RESPONSE
In Reply On behalf of the PD REHAB Collaborative Group, we
are pleased that the PD REHAB Trial1 has prompted debate.
The issues raised are common to the 3 letters2-4 and all were
covered in the original article.1
Eligibility was based on the uncertainty principle. Inves-
tigators were mostly uncertain of the value of physiotherapy
and occupational therapy in patients with mild to moderate
Parkinson disease (PD). So, the results of the trial can only be
applied to patients withmild tomoderate disease. This is not
in conflict with our Cochrane review of physical therapies in
PD, which showed short-term benefits inmotor function and
activities of daily living but, importantly, not in quality of life
in more severe disease.5
TheNottinghamExtendedActivitiesofDailyLivingScalewas
usedas theprimaryoutcomeso thatanybenefits couldbecom-
paredwith those in other disease areaswhere it has been used
before(ie,strokeandaging). IthasbeenusedinpreviousPDtrials
andcorrelatedwellwith theUnifiedParkinson’sDiseaseRating
Scaleactivitiesofdaily livingscale inourpilotPD/OTtrial.6This
approach precluded the use of an individualized outcome as
suggestedbydeVriesetal4 in their letter.AlthoughtheNotting-
hamExtendedActivitiesofDailyLivingScaledoesnotdirectly
address gait and transfers, it does assess issues suchaswalking
outside, using public transport, and climbing stairs, which are
ofmore practical use andmore important to patients. Indeed,
ourpatientadvisorygroupsupportedtheuseof theNottingham
ExtendedActivities ofDaily Living as theprimary outcome for
this very reason.
We too were surprised by the low dose of both therapies,
but this is what is being delivered to patients with mild to
moderate PD in the National Health Service (NHS) today. We
do not agree with Mestriner3 that this is nonadherence; it is a
low-dose intervention. We were informed by therapists
before the trial that both physiotherapists and occupational
therapists see such referrals, so they wanted the combined
design of the PD REHAB Trial. A large number of centers
were deliberately secured to aid recruitment and to ensure
that the results could be generalized across the NHS. There-
fore, PD REHAB is a pragmatic trial of standard care in the
NHS and not a study of a novel high-intensity form of
therapy. This is the design that the funder, the NHS Health
Technology Assessment Programme, wanted to inform deci-
sions to be made about the future delivery of such services
within the NHS.
The PDREHABTrial is a high-quality, precise, adequately
powered study that demonstrates that low-dose, patient-
centered, goal-directed physiotherapy and occupational
therapy in early PD is ineffective.We cannot ignore or seek to
discredit important results that we do not find palatable. We
owe it to our patients to deliver the best care possible, so fu-
ture research should explore the development and testing of
more structured and intensive physical and occupational
therapy programs in patients with all stages of PD.
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